*.- The company provided EPS guidance of $13.400-14.700 for the period, compared to the Thomson Reuters Consensus EPS Estimate of $15.050.
*.- The Company issued revenue guidance of $3.02 billion-3.18 billion, compared to the consensus revenue estimate of $3.11 billion.
*.- Jazz Pharmaceuticals also updated its FY21 guidance to $13.40-14.70 EPS.
JAZZ stock opened at $181.13 on Thursday. The firm has a market cap of $10.31 billion, a PE ratio of 19.86, a price-to-earnings-growth ratio of 0.74 and a beta of 1.05. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.21 and a quick ratio of 4.06. The company's fifty day simple moving average is $173.03. Jazz Pharmaceuticals has a fifty-two week low of $103.46 and a fifty-two week high of $189.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, May 4th. The specialty pharmaceutical company reported $3.92 EPS for the quarter, beating the Zacks' consensus estimate of $3.09 by $0.83. Jazz Pharmaceuticals had a return on equity of 22.95% and a net margin of 21.27%. The firm had revenue of $607.58 million for the quarter, compared to analyst estimates of $613.07 million. During the same period last year, the company earned $0.45 EPS. The business's quarterly revenue was up 13.6% compared to the same quarter last year. As a group, equities research analysts forecast that Jazz Pharmaceuticals will post 13.99 earnings per share for the current year.
Several research analysts have weighed in on the company. Cowen lifted their target price on Jazz Pharmaceuticals from $190.00 to $200.00 and gave the stock an outperform rating in a report on Wednesday, February 24th. SVB Leerink reissued a buy rating on shares of Jazz Pharmaceuticals in a research note on Sunday, May 9th. Piper Sandler reissued a buy rating and issued a $214.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, May 24th. Morgan Stanley lifted their price target on Jazz Pharmaceuticals from $162.00 to $176.00 and gave the company an equal weight rating in a research note on Thursday, April 1st. Finally, TheStreet raised Jazz Pharmaceuticals from a c+ rating to a b rating in a research note on Wednesday, May 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and fifteen have issued a buy rating to the company's stock. The company has an average rating of Buy and a consensus target price of $192.76.
In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $164.24, for a total value of $246,360.00. Following the completion of the sale, the chief executive officer now directly owns 321,841 shares in the company, valued at $52,859,165.84. The sale was disclosed in a filing with the SEC, which is available at this link.
Also, CEO Bruce C. Cozadd sold 500 shares of the business's stock in a transaction that occurred on Wednesday, May 5th. The shares were sold at an average price of $170.00, for a total value of $85,000.00.
Following the completion of the sale, the chief executive officer now owns 321,841 shares of the company's stock, valued at $54,712,970. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,500 shares of company stock valued at $578,800. Corporate insiders own 4.60% of the company's stock.